[CLVS] Clovis Oncology, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 533.24 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 45.35 Change: 0.32 (0.71%)
Ext. hours: Change: 0 (0%)

chart CLVS

Refresh chart

Strongest Trends Summary For CLVS

CLVS is in the medium-term up 146% in 2 years and down -74% below S&P in 3 years. In the long-term down -94% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements w

Fundamental Ratios
Shares Outstanding38.39 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV2.11 Price/Cash Per Share
Price/Free Cash Flow-4.47 ROA-27.31% ROE-76.19% ROI
Current Ratio7.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.22
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.19 M Cash From Investing Activities-143.03 M Cash From Operating Activities-48.41 M Gross Profit
Net Profit-63.14 M Operating Profit-64.22 M Total Assets704.71 M Total Current Assets441.7 M
Total Current Liabilities55.68 M Total Debt287.5 M Total Liabilities452.12 M Total Revenue
Technical Data
High 52 week32.67 Low 52 week3.12 Last close3.21 Last change2.88%
RSI20.96 Average true range0.29 Beta1.33 Volume1.42 M
Simple moving average 20 days-17.78% Simple moving average 50 days-36.87% Simple moving average 200 days-80.19%
Performance Data
Performance Week1.58% Performance Month-43.19% Performance Quart-73.97% Performance Half-84.87%
Performance Year-87.99% Performance Year-to-date-82.13% Volatility daily3.69% Volatility weekly8.26%
Volatility monthly16.93% Volatility yearly58.65% Relative Volume1318.58% Average Volume3.84 M
New High New Low

News

2021-04-10 08:30:00 | Clovis Oncology Highlights Rubraca® rucaparib Clinical Data at AACR Virtual Annual Meeting 2021

2021-03-25 11:30:03 | Why Is Clovis CLVS Up 4.4% Since Last Earnings Report?

2021-03-22 09:50:38 | Return On Capital Employed Overview: Clovis Oncology

2021-03-22 08:34:12 | Are Options Traders Betting on a Big Move in Clovis Oncology CLVS Stock?

2021-03-22 07:17:11 | Clovis CLVS Stock Jumps 47.7%: Will It Continue to Soar?

2021-03-19 16:30:00 | Why Clovis Oncology Stock Skyrocketed Today

2021-03-19 11:13:50 | Return On Capital Employed Overview: Clovis Oncology

2021-03-19 09:24:00 | 5 Top Stock Gainers for Friday: FedEx, Dollar General, Clovis

2021-03-19 08:19:00 | Clovis Oncology stock soars after ovarian cancer treatment meets primary endpoint

2021-03-19 08:00:00 | Clovis Oncology’s Rubraca® rucaparib Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation

2021-03-19 06:50:00 | Clovis Oncology Skyrockets on Ovarian Cancer Drug Success

2021-03-02 10:21:24 | Understanding Clovis Oncology's Unusual Options Activity

2021-02-23 09:24:35 | Clovis Oncology: Q4 Earnings Insights

2021-02-23 08:00:00 | Clovis Oncology Announces 2020 Operating Results

2021-02-23 06:30:00 | Clovis Oncology, Inc. to Host Earnings Call

2021-02-22 10:14:21 | Earnings Preview for Clovis Oncology

2021-02-17 08:00:00 | Clovis Oncology to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Webcast Conference Call on February 23

2021-02-11 08:00:00 | Clovis Oncology Presents Data in Advanced Prostate Cancer at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

2021-02-06 02:41:11 | Could The Clovis Oncology, Inc. NASDAQ:CLVS Ownership Structure Tell Us Something Useful?

2021-02-04 08:00:00 | Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

2021-02-02 10:00:03 | Alexion ALXN to Report Q4 Earnings: What's in the Cards?

2021-01-11 08:00:00 | Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020

2020-12-30 06:49:11 | Clovis CLVS Seeks Permission for Clinical Study on Novel Drug

2020-12-29 08:00:00 | Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

2020-12-22 10:28:03 | Company News for Dec 22, 2020

2020-12-22 10:05:03 | Clovis' CLVS Rubraca Confirmatory Study Meets Endpoint

2020-12-21 10:05:16 | Looking Into Clovis Oncology's Return On Capital Employed

2020-12-21 08:00:00 | Clovis Oncology’s Rubraca® rucaparib Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

2020-12-16 22:51:55 | Is CLVS A Good Stock To Buy Now?

2020-12-10 08:55:01 | Is the Options Market Predicting a Spike in Clovis Oncology CLVS Stock?

2020-12-05 11:32:04 | Clovis CLVS Up 18.6% Since Last Earnings Report: Can It Continue?

2020-11-24 18:06:00 | Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024

2020-11-20 08:00:00 | Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference

2020-11-08 07:40:16 | Clovis Oncology, Inc. NASDAQ:CLVS Analysts Are Cutting Their Estimates: Here's What You Need To Know

2020-11-06 10:43:03 | Clovis CLVS Q3 Earnings Top, Sales Show Coronavirus Impact

2020-11-05 09:25:02 | Clovis Oncology CLVS Reports Q3 Loss, Lags Revenue Estimates

2020-11-05 08:05:00 | Clovis Oncology Announces Third Quarter 2020 Operating Results

2020-11-05 08:02:00 | Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes

2020-10-29 12:35:04 | Will Clovis Oncology CLVS Report Negative Earnings Next Week? What You Should Know

2020-10-20 16:05:00 | Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5

2020-10-14 22:15:23 | Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc CLVS

2020-10-13 06:47:33 | How Much Is Clovis Oncology, Inc. NASDAQ:CLVS Paying Its CEO?

2020-09-17 03:05:00 | New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline

2020-09-10 08:05:00 | Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society IGCS Digital Annual Global Meeting

2020-09-09 08:05:00 | Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020

2020-09-08 16:19:00 | Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

2020-09-08 08:53:12 | Are Options Traders Betting on a Big Move in Clovis Oncology CLVS Stock?

2020-09-05 11:31:03 | Clovis CLVS Down 17.3% Since Last Earnings Report: Can It Rebound?

2020-08-27 09:58:02 | ROCE Insights For Clovis Oncology

2020-08-27 08:02:06 | The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test